NEW NEOADJUVANT INDICATION FOR PETUZUMAB
EU LABEL
PERTUZUMAB
•
Neoadjuvant Treatment of Breast Cancer
PERTUZUMAB is indicated for use in combination with trastuzumab
and chemotherapy for the neoadjuvant treatment of adult patients with
HER2-positive, locally advanced, inflammatory, or early stage breast
cancer at high risk of recurrence
•
Metastatic Breast Cancer
PERTUZUMAB is indicated for use in combination with trastuzumab
and docetaxel in adult patients with HER2-positive metastatic or locally
recurrent unresectable breast cancer, who have not received previous
anti-HER2 therapy or chemotherapy for their metastatic disease.
NEW
EU LABEL
28/07/2015
